Saturday, 31 October 2026European Markets

BELYSSE GROUP Stock Was 12.57% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with BELYSSE GROUP (BELYS.BR) rising 12.57% to €0.79 on Wednesday, after three successive sessions in a row of losses. BEL 20 jumped 0.86% to €3,695.03, after two consecutive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

About BELYSSE GROUP

Belysse Group NV produces and sells textile floor coverings for commercial and residential applications in Europe, North America, and internationally. The company designs, manufactures, and distributes broadloom carpets and modular carpet tiles primarily for offices and public projects. It commercializes its products under the Bentley, modulyss, arc edition, and ITC brands. The company was formerly known as Balta Group NV and changed its name to Belysse Group NV in October 2022. Belysse Group NV was founded in 1964 and is headquartered in Waregem, Belgium. Belysse Group NV is a subsidiary of LSF9 Belysse Holdco S.à r.l.

Earnings Per Share

As for profitability, BELYSSE GROUP has a trailing twelve months EPS of €-0.31.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BELYSSE GROUP's stock is considered to be overbought (>=80).

Volatility

BELYSSE GROUP's last week, last month's, and last quarter's current intraday variation average was 0.61%, 0.39%, and 3.51%.

BELYSSE GROUP's highest amplitude of average volatility was 3.46% (last week), 2.87% (last month), and 3.51% (last quarter).

Volume

Today's last reported volume for BELYSSE GROUP is 10816 which is 7.35% above its average volume of 10075.

More news about BELYSSE GROUP (BELYS.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com